Author: Ken Dropiewski

Inari Medical, now part of Stryker, launches the all-new InThrill® Thrombectomy System, designed to address arteriovenous access and small vessel thrombus cases

PORTAGE, Mich., July 29, 2025 /PRNewswire/ — Inari Medical, now part of Stryker (NYSE: SYK), a global leader in medical technologies, announced the launch of its next-generation InThrill Thrombectomy System, the first and only purpose-built small vessel and arteriovenous (AV) access…

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

Trial Investigates Use of Auryon Atherectomy System in Cases with Challenging Below-the-Knee Blockages LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced enrollment of the first […]

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its groundbreaking MAGiC Sweep™ catheter. MAGiC Sweep is the world’s first robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose and treat complex arrhythmia patients.

HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

Southlake, TX, July 24, 2025 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the fiscal year ended April 30, 2025, and provided a business update highlighting significant strategic progress.

GNT Pharma Receives Regulatory Approval to Initiate Multinational Phase 3 Clinical Trials for its Breakthrough Stroke Therapy ‘ Nelonemdaz™ ‘

NEW YORK, July 24, 2025 /PRNewswire/ — GNT Pharma, a late-stage biopharmaceutical company with operations in Seoul and New York, today announced its IND Application to commence Global Phase 3 Clinical Trials of its lead drug Nelonemdaz, has been approved by MFDS – South Korea’s…

Heart Failure Society of America Celebrates 30 Years with Lineup of Visionary Leaders at Annual Scientific Meeting 2025

Saturday Plenary to Spotlight Innovations in Heart Failure Research, AI, and Future Care Models WASHINGTON, July 24, 2025 /PRNewswire/ — The Heart Failure Society of America (HFSA) is marking 30 years of leadership in heart failure care with a dynamic celebration at the HFSA Annual…

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of […]

Imperative Care Secures FDA Clearance and Initial Cases of the Zoom 7X Catheter, the Newest Innovation in Ischemic Stroke Treatment

CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and first patient cases with the latest advancement in ischemic stroke treatment – the novel Zoom 7X Catheter for aspiration thrombectomy procedures. The newest addition to the company’s comprehensive Zoom Stroke System, the Zoom 7X Catheter […]